Immuno Biochem Corporation is a privately-held biopharmaceutical company focused on discovering unique tumor targets and developing novel biological therapeutics, particularly in oncology and immuno-oncology. The company utilizes high-throughput functional screens, bioinformatics, and AI/ML to explore the cancer cell secretome, aiming to identify novel tumor targets for targeted therapeutic modalities. Their innovative approach has led to the development of antibody-drug conjugates (ADCs) and immunostimulatory ADCs (ISACs) that show efficacy in challenging solid tumors, including triple-negative breast cancer and pancreatic cancer. Immuno Biochem collaborates with Immuno Gen to advance their ADCs, enhancing their research and development capabilities and expanding their innovative pipeline.
Something looks off?